NetworkNewsWire Announces Publication Highlighting

NEW YORK, NY--(Marketwired - Sep 20, 2017) - NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring Lexaria Bioscience Corp. ( CSE : LXX ) ( OTCQB : LXRP ), a client of NNW that develops and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids.

The publication, entitled, "Advances in Drug Delivery Hold the Promise of Reducing Inevitable Side Effects," discusses the potential of cannabinoids as efficient treatment options.

To view the full publication, visit: https://www.networknewswire.com/advances-drug...e-effects/

"Research findings in the cannabinoid field continue to astonish and elate. In August 2017, Lexaria Bioscience announced ( http://nnw.fm/h7aG8 ) the world's first clinical study on human volunteers of cannabidiol (CBD) within Lexaria's high absorption TurboCBD™ product. The study will evaluate the effects of CBD on cardiovascular health and cognitive function. Lexaria's TurboCBD, a brand of technologically enhanced, high absorption hemp oil capsules, came to market in March 2017. Its CBD content is fortified with high-quality American ginseng and ginkgo biloba for support of enhanced focus and memory, and reduced stress and fatigue.

"TurboCBD capsules contain a combination of CBD and minute quantities of long chain fatty acids like sunflower oil, utilizing a proprietary technology to create an amalgam that increases the ability of the human gastrointestinal system to absorb CBD. In vitro and human focus study testing has shown increases in CBD absorption using Lexaria's technology by as much as 5-10 times more than conventional preparations. Those studies also demonstrated rapid onset of action in as little as 15 minutes."

About Lexaria Lexaria Bioscience Corp. has developed and out-licenses its disruptive technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and was granted its first patents in the USA and in Australia related to edible forms of cannabinoids. Lexaria's technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit www.lexariabioscience.com .

About NetworkNewsWire NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today's market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

Forward-Looking Statements This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.